Tenderwize
Zurück zur Suche

Open House Biologics Discount Agreement for Lutropin alfa / Follitropin alfa

Techniker Krankenkasse·Hamburg, Germany·Deadline May 30, 2027 · 276 days left·Open·Supplies
Registrieren zum SpeichernOpen documents
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2025-09 - Lutropin alfa / Follitropin alfa (Wirkstoffkombination)

62/100

Opportunity Score

Needs reviewMedium complexity
SuppliesOpen
Warum diese Bewertung?

Chance

62 / 100

Komplexität

58 / 100

Risikofaktoren

Portal submission is not allowed; contracts must be submitted by email with qualified electronic signature or by post...

Only pharmaceutical undertakings meeting the AMG and authorisation requirements may participate.

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration until May 2027
  • Supply-related Open House discount agreements for pharmaceutical products.
  • Product scope: Lutropin alfa / Follitropin alfa combination.
Vollständige Zusammenfassung anzeigen

This is an Open House supply arrangement by Techniker Krankenkasse (with HEK and hkk listed as participating buyers) for pharmaceutical products, specifically the Lutropin alfa / Follitropin alfa combination. The contract is non-exclusive, with uniform terms and no individual negotiations. The term is up to 24 months from 2025-06-01 and ends no later than 2027-05-31. Submission is not via the portal; contracts must be sent by email with qualified electronic signature or by post. No contract value is stated.

Risiken

Portal submission is not allowed; contracts must be submitted by email with qualified electronic signature or by post...

Only pharmaceutical undertakings meeting the AMG and authorisation requirements may participate.

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Applicant must be a pharmaceutical undertaking within the meaning of Section 4(18) AMG for the offered medicinal products.
  • Applicant must have its seat in the AMG territory, another EU Member State, or another EEA state.
  • Applicant must hold a valid marketing authorisation for the relevant medicinal products or otherwise be entitled to place them on the market in its own name.

Auftraggeber

Ort

Hamburg, DEU

Kennung

992-80116-93

Tätigkeit

Health

Lose (1)

LOT-0001

Open House Biologics Discount Agreement for Lutropin alfa / Follitropin alfa

Single lot covering discount agreements under Section 130a(8) SGB V for the Lutropin alfa / Follitropin alfa medicinal product combination. The notice states the arrangement is open to all suitable pharmaceutical companies meeting the stated conditions, with no exclusivity and no individual negotiation. Scope and eligibility details are in the participation and contract documents.

SuppliesEU fundedElectronic submission

Ort

DE600, Germany

Dauer

May 2025 - May 2027

Kategorie

Pharmaceutical products

Frist

Deadline May 30, 2027

Vergabedetails

Veröffentlichungsdatum
22 Apr 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
262656-2025

Dokumente (1)

Vergabedokument 1

Ähnliche Ausschreibungen

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3